Handok

한독 · 002390

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$82.5M (₩113.8B)

Overview

Handok is a Korean pharmaceutical company that makes and distributes prescription medicines, medical devices, and health-functional foods, products used by patients and healthcare providers across South Korea.

Its portfolio includes branded medicines for conditions such as diabetes alongside consumer health products. Listed on KOSPI, South Korea's main stock exchange, the company operates across multiple business lines, including a property-leasing segment alongside its core pharmaceutical activities.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$387.8M

▲ +5.5% YoY

Operating profit · FY2025

US$2.4M

▲ +511.2% YoY

Net income · FY2025

−US$1.6M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$378.8M(₩522.7B)	US$367.7M(₩507.4B)	US$387.8M(₩535.1B)
Operating profit	US$9.1M(₩12.6B)	US$390.2K(₩538.5M)	US$2.4M(₩3.3B)
Net income	−US$21M(−₩28.9B)	−US$38.2M(−₩52.7B)	−US$1.6M(−₩2.2B)

Revenue

FY2023US$378.8M
FY2024US$367.7M
FY2025US$387.8M

Operating profit

FY2023US$9.1M
FY2024US$390.2K
FY2025US$2.4M

Net income

FY2023−US$21M
FY2024−US$38.2M
FY2025−US$1.6M

Key ratios (FY2025)

ROE

-0.8%

Debt/Eq

184.1%

Op. margin

0.6%

Net margin

-0.4%

Rev. YoY

▲ +5.5%

Why it matters

Handok maintains a manufacturing plant in Eumseong County and a dedicated research institute in Seoul's Magok district, giving it both production and R&D operations within Korea.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?